🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

IBD Innovate is the only conference that brings together the entire IBD R&D ecosystem, including scientists, investors, entrepreneurs, and patients, to learn, share, and connect on novel solutions for patients. Register now to save: bit.ly/4g9QSmG #IBDInnovate25

1st intestinal ultrasound training at a North American IBD Conference is complete! Incredible day and could not have happened without the support and work from Crohn's & Colitis Foundation American Gastroenterological Association (AGA) InternationalBowelUS iUSCAN collaborating together.

New InternationalBowelUS Workshop 1 in 🇪🇺🇨🇿 The 16th IBUS Module 1 Workshop will take place from Friday, June 20th, 2025 to Saturday, June 21st, 2025 in Prague, Czech Republic. This IBUS workshop, the 1st module of the IBUS Curriculum, has been developed by international experts

InternationalBowelUS president shares IMPRESSIVE Growth 📈with IUS central reading now in 8 clinical trials! ⭐️#krisztinagecse Christian Kerri Mariangela Allocca Rune Wilkens iUSCAN

An honour to present on behalf of Ralley Prentice & our team aiming to enhance care for 🤰 women with #IBD: Active disease on IUS in pregnancy associated with ⬆️ adverse pregnancy outcomes. We suggest #IUS monitoring in T1 and T2 and target IUS remission where possible #ECCO2025

Exciting news! Today, the Delphi consensus results of the EXTENT study were presented at the ECCO 2025 in Berlin! Exploring IUS as a more accessible tool to assess bowel damage in disease modification trials. academic.oup.com/ecco-jcc/artic… #IBUS #ECCO #IBD #MedicalResearch

I am delighted to be part of this prospective inception cohort study led by Gorm Roager Madsen InternationalBowelUS predicts long-term steroid-free clinical remission in #ulcerativecolitis. "In conclusion, our study highlights transmural remission as an achievable treatment target in UC,

Exciting new research from our team in @CGHjournal! 🔬 Huge congratulations to first author Gorm Roager Madsen for leading this important study on #Crohnsdisease! We investigated #transmural behavior using InternationalBowelUS (#IUS) in a large inception cohort of new-onset Crohn's

🚨The intestinal barrier: a pivotal role in health, inflammation and cancer The Lancet Gastroenterology & Hepatology PI & II studies exploring ways to improve barrier function 👇🏽👇 pubmed.ncbi.nlm.nih.gov/40086468/ Y-ECCO Florian Rieder Aline Charabaty, MD, FACG, AGAF Axel Dignass Irina Blumenstein Remo Panaccione, MD, FRCPC Fernando Gomollón alessandro armuzzi

We are off to a great start! Here’s a recap of the Evening Symposium at the IBUS Module 1 Workshop in Houston. Exciting discussions, insights, and innovation in ultrasound! #IBUS #Workshop #Ultrasound #IBUSHouston

What happens if patients take the lead in an IBD project? Result: A wholly patient-led paper on ''What it means to live with IBD'. 🧵on how our patient-public involvement (PPI) #IBD came about.... #Crohns #colitis #PPIE #patientinvolvement medrxiv.org/content/10.110…

IBUS-SAS Validated for #ulcerativeColitis by Gabriele Dragoni and excellent co-workers 👏 Conclusion: The IBUS-SAS has an optimal performance in the assessment of UC endoscopic activity, despite having been initially developed for CD. Therefore, it might be adopted as reference

24 M new Dx UC presenting with ASUC. Responds to IV steroids in hospital and starts 5-ASA, AZA (now therapeutic) and pred taper post discharge. IUS is performed 8 weeks post discharge. Without knowing symptoms, based on IUS findings, what would be next best step in management?

There is NO planet B 🌍 Help us explore how sustainable our IBD care really is If you’re a healthcare professional working in IBD, please take 5 min to answer this short survey 🙏🏻your input matters! ➡️forms.gle/EtaMUjGPn14KFH… Tommaso Lorenzo Parigi olga nardone

📢 Save the date! Join us on December 15, 2025 in Leuven, Belgium for the 1st IBUS Workshop for the Industry. 📌Don’t miss out - register by October 13th on our website: ibus-group.org/event/intestin…

Exciting new study re-confirms the use of IBUS-SAS in #Ulcerativecolitis: Consequently, an IBUS‐SAS below 15.9 effectively ruled out endoscopic disease activity in our cohort, underscoring the potential of IUS to non-invasively exclude relevant disease activity and potentially

We are excited to share the launch of Pfizer Inc.’s PRISM program, a groundbreaking group of healthcare providers, patients, professional societies & industry leaders to make #IUS more widely accessible globally. Read more here: pfizer.com/news/announcem… Our very own SAIA is proud

💡Nature Portfolio #Domain #Specific #NLP #Rivals 70 Billion Parameter #LLM #Giants in #Clinical #AI. Our custom 110M-parameter transformer finetuned on #IBD textbooks & guidelines (#AGA #ACG #ECCO) achieved near or better than state-of-the-art performance nature.com/articles/s4174…